Universal Detection Technology (OTC Bulletin Board: UDTT; FWB: PO8), a developer of early-warning monitoring technologies to protect people from bioterrorism and other infectious health threats, announced today that on May 19th, 2006 it has been featured in Voice of America News. The article and the accompanying video explain the technology behind company's BSM-2000 line of bio-terror detection systems. The video clip includes interviews with the inventor of the technology as well as UDTT's Director of R&D, Mr. Amir Ettehadieh.
"We hope that media coverage will bring more visibility for our valuable services and technologies," said Ettehadieh. "Our core mission is to contribute to nation's awareness and preparedness against bioterrorism. This is a very real threat and unfortunately little are we prepared to cope with a disaster. Being aware and ready to counter an attack with germs such as anthrax is the first step in containing the catastrophic consequences of such an attack," he added.
A copy of the article can be seen at http://www.udetection.com/articles/voa0506.htm. The video can be viewed at http://www.udetection.com/pressroom-video-VOA0506.htm .
About Universal Detection Technology
Universal Detection Technology (UDTT), founded in 1973, is a developer of monitoring technologies, including bio-terrorism detection devices. Universal Detection Technology, in cooperation with NASA's Jet Propulsion Laboratory (JPL) has developed the BSM-2000, a bacterial spore and anthrax spore monitoring device, which combines JPL's spore detection technology with UDTT's aerosol capture device. For more information, please visit http://www.udetection.com.
Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. These risks and uncertainties include, among other things, the funding of amounts of capital adequate to provide for our working capital needs and our timely repayment of debt; the ability of SSI to generate sales and increase visibility of the BSM-2000 based on its contacts and relationships in the United States; our ability to timely and cost effectively complete the development and testing of our products targeted to the bio-chemical market; our ability to commercially produce our products on a profitable basis; commercial acceptance of our products; product price volatility; product demand; market competition and general economic conditions and; other factors described in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.